After participating in this educational activity, attendees should be able to:

1. Describe the utility of CGRP receptor antagonists in the prevention and treatment of migraines
2. Evaluate the efficacy of eptinezumab for migraine prevention
3. Assess the safety and efficacy of eptinezumab for treatment of active moderate/severe migraines

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.